RecruitingPhase 2NCT05564390
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Studying Myelodysplastic/myeloproliferative disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Jerald P RadichSWOG Cancer Research Network
- Intervention
- Allogeneic Hematopoietic Stem Cell Transplantation(procedure)
- Enrollment
- 2000 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2029
Study locations (30)
- University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
- Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
- Banner University Medical Center - Tucson, Tucson, Arizona, United States
- University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
- University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
- Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California, United States
- Kaiser Permanente Dublin, Dublin, California, United States
- Kaiser Permanente-Fremont, Fremont, California, United States
- Kaiser Permanente Fresno Orchard Plaza, Fresno, California, United States
- Kaiser Permanente-Fresno, Fresno, California, United States
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States
- Tibor Rubin VA Medical Center, Long Beach, California, United States
- Cedars Sinai Medical Center, Los Angeles, California, United States
- Kaiser Permanente- Modesto MOB II, Modesto, California, United States
- Kaiser Permanente-Modesto, Modesto, California, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05564390 on ClinicalTrials.govOther trials for Myelodysplastic/myeloproliferative disease
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06532084Sorafenib Relapase Prophylaxis After HCT With PTBCy RegimenSt. Petersburg State Pavlov Medical University
- RECRUITINGPHASE2NCT05788679A Study Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects With MDSKarolinska University Hospital
- RECRUITINGPHASE2NCT04493164CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeM.D. Anderson Cancer Center
See all trials for Myelodysplastic/myeloproliferative disease →